Critical Reviews in Oncology/hematology
Overview
Critical Reviews in Oncology/Hematology is a reputable journal that provides comprehensive and insightful reviews on the latest advancements in the field of oncology and hematology. With a focus on critical analysis and evidence-based discussions, this journal serves as a valuable resource for researchers, clinicians, and healthcare professionals seeking to stay updated on cutting-edge research, treatment strategies, and emerging trends in the management of cancer and blood disorders.
Details
Details
Abbr.
Crit Rev Oncol Hematol
Start
1983
End
Continuing
Frequency
Twelve no. a year
p-ISSN
1040-8428
e-ISSN
1879-0461
Country
Netherlands
Language
English
Specialty
Hematology
Metrics
Metrics
h-index / Ranks: 1534
144
SJR / Ranks: 1816
1572
CiteScore / Ranks: 1286
10.50
JIF / Ranks: 1060
6.2
Recent Articles
1.
Zhao J, Tang B, Shen P, Zeng H, Wei Q
Crit Rev Oncol Hematol
. 2025 Mar;
:104698.
PMID: 40089046
Poly (ADP-ribose) polymerase (PARP) inhibitors have revolutionized the treatment of many cancers. Metastatic castration-resistant prostate cancer (mCRPC) is an area where PARP inhibitors are intensively studied; the efficacy with PARP...
2.
Noury H, Rahdar A, Ferreira L, Jamalpoor Z
Crit Rev Oncol Hematol
. 2025 Mar;
:104701.
PMID: 40086770
The convergence of artificial intelligence (AI) and nanomedicine has revolutionized the design of smart multifunctional nanocarriers (SMNs) for drug and gene delivery, offering unprecedented precision, efficiency, and personalization in therapeutic...
3.
The Dual Role of Chaperone-mediated Autophagy in the Response and Resistance to Cancer Immunotherapy
Saberiyan M, Gholami S, Ejlalidiz M, Manshadi M, Anoorabadi P, Noorabadi P, et al.
Crit Rev Oncol Hematol
. 2025 Mar;
:104700.
PMID: 40086769
Cancer immunotherapy has become a revolutionary strategy in oncology, utilizing the host immune system to fight malignancies. Notwithstanding major progress, obstacles such as immune evasion by tumors and the development...
4.
Arenhardt M, Giannecchini G, de Andrade D, Gomes L, Dos Santos M, da Silva J, et al.
Crit Rev Oncol Hematol
. 2025 Mar;
210:104695.
PMID: 40068805
Introduction: Vulvar squamous cell carcinoma (VSCC) is a rare gynecological tumor with limited treatment options for advanced stages. Current chemotherapy, adapted from cervical cancer protocols, often results in poor outcomes....
5.
Flora Z, Zagouri F, Dimopoulos M, Andrikopoulou A
Crit Rev Oncol Hematol
. 2025 Mar;
:104696.
PMID: 40068804
Approximately 1 in 10 women diagnosed with breast cancer before the age of 35 carry germline BRCA pathogenic/likely pathogenic variants. Poly (ADP-ribose) polymerase (PARP) inhibitors have been recently approved in...
6.
Cannarozzi A, Biscaglia G, Parente P, Latiano T, Gentile A, Ciardiello D, et al.
Crit Rev Oncol Hematol
. 2025 Mar;
:104694.
PMID: 40064251
Colorectal cancer (CRC) is the third most common and second most deadly cancer worldwide. Despite advances in screening and treatment, CRC is heterogeneous and the response to therapy varies significantly,...
7.
Hasan N, Yazdanpanah O, Harris J, Nagasaka M
Crit Rev Oncol Hematol
. 2025 Mar;
210:104676.
PMID: 40064250
Consolidative radiation is increasingly regarded as an effective treatment for oligometastatic and oligoprogressive non-small cell lung cancer (NSCLC). This systematic review examines the clinical evidence on the significance of consolidative...
8.
Gaudio M, Vatteroni G, De Sanctis R, Gerosa R, Benvenuti C, Canzian J, et al.
Crit Rev Oncol Hematol
. 2025 Mar;
:104681.
PMID: 40058742
The assessment of neoadjuvant treatment's response is critical for selecting the most suitable therapeutic options for patients with breast cancer to reduce the need for invasive local therapies. Breast magnetic...
9.
Farahavar G, Abolmaali S, Biabanikhankahdani R, Tamaddon A
Crit Rev Oncol Hematol
. 2025 Mar;
:104691.
PMID: 40058741
Malignancies maintain a high rate of mortality worldwide each year, requiring the development of novel therapeutic platforms. Immunotherapy approaches are considered a revolutionary treatment for overcoming malignancies. Photodynamic therapy (PDT)...
10.
Pinto A, Dominguez M, Gomez-Iturriaga A, Rodriguez-Vida A, Vallejo-Casas J, Castro E
Crit Rev Oncol Hematol
. 2025 Mar;
210:104678.
PMID: 40058740
The treatment of metastatic castration-resistant prostate cancer (mCRPC) has been rapidly evolving over the last two decades. The advent of new androgen receptor pathway inhibitors (ARPIs) such as abiraterone acetate...